Curanex Pharmaceuticals Inc Common Stock (CURX) is a publicly traded the market company. As of May 21, 2026, CURX trades at $0.33 with a market cap of $8.53M and a P/E ratio of -1.91. CURX moved +0.00% today. Year to date, CURX is -9.92%; over the trailing twelve months it is flat. Its 52-week range spans $0.26 to $9.18. Rallies surfaces CURX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Curanex Completes GMP Batch, Reports Favorable Toxicology, Targets Q4 2026 IND: Curanex completed a GMP-compliant pilot-scale batch of Phyto-N and a 28-day dose-range toxicology study in rats and dogs with no treatment-related adverse findings, supporting its planned Q4 2026 IND submission for ulcerative colitis. The company also expanded its pipeline to target a $2.54 billion cancer cachexia market and holds $4 million cash.
| Metric | Value |
|---|---|
| Price | $0.33 |
| Market Cap | $8.53M |
| P/E Ratio | -1.91 |
| EPS | $-0.17 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.18 |
| 52-Week Low | $0.26 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-4.23M |
| Gross Margin | 0.00% |
CURX analyst coverage data. Average price target: $0.00.